Notice of Request for Public Comment on Proposed Update to the Bright Futures Periodicity Schedule as Part of the HRSA-Supported Preventive Services Guidelines for Infants, Children, and Adolescents, 66197-66198 [2022-23845]
Download as PDF
<![CDATA[
khammond on DSKJM1Z7X2PROD with NOTICES
Federal Register / Vol. 87, No. 211 / Wednesday, November 2, 2022 / Notices
and the Japanese Pharmaceutical
Manufacturers Association. The
Standing Members of the ICH
Association include Health Canada and
Swissmedic. Additionally, the
Membership of ICH has expanded to
include other regulatory authorities and
industry associations from around the
world (https://www.ich.org/).
ICH works by involving technical
experts from both regulators and
industry parties in detailed technical
harmonization work and the application
of a science-based approach to
harmonization through a consensusdriven process that results in the
development of ICH guidelines. The
regulators around the world are
committed to consistently adopting
these consensus-based guidelines,
realizing the benefits for patients and for
industry.
As a Founding Regulatory Member of
ICH, FDA plays a major role in the
development of each of the ICH
guidelines, which FDA then adopts and
issues as guidance for industry. FDA’s
guidance documents do not establish
legally enforceable responsibilities.
Instead, they describe the Agency’s
current thinking on a topic and should
be viewed only as recommendations,
unless specific regulatory or statutory
requirements are cited.
In the Federal Register of October 5,
2021 (86 FR 54982), FDA published a
notice announcing the availability of a
draft guidance entitled ‘‘S1B(R1)
Addendum to S1B Testing for
Carcinogenicity of Pharmaceuticals.’’
The notice gave interested persons an
opportunity to submit comments by
December 6, 2021.
After consideration of the comments
received and revisions to the guideline,
a final draft of the guideline was
submitted to the ICH Assembly and
endorsed by the regulatory agencies on
August 4, 2022.
The final guidance provides guidance
on expanding the testing scheme for
assessing human carcinogenic risk of
pharmaceuticals by introducing an
additional approach that is not
described in the original S1B Guideline
and also adds a plasma exposure ratiobased approach for setting the high dose
in the rasH2-Tg mouse model. This
guidance finalizes the draft guidance
issued on October 5, 2021.
This guidance is being issued
consistent with FDA’s good guidance
practices regulation (21 CFR 10.115).
The guidance represents the current
thinking of FDA. It does not establish
any rights for any person and is not
binding on FDA or the public. You can
use an alternative approach if it satisfies
VerDate Sep<11>2014
16:38 Nov 01, 2022
Jkt 259001
the requirements of the applicable
statutes and regulations.
II. Paperwork Reduction Act of 1995
While this guidance contains no
collection of information, it does refer to
previously approved FDA collections of
information. Therefore, clearance by the
Office of Management and Budget
(OMB) under the Paperwork Reduction
Act of 1995 (PRA) (44 U.S.C. 3501–
3521) is not required for this guidance.
The previously approved collections of
information are subject to review by
OMB under the PRA. The collections of
information in 21 CFR part 312 have
been approved under OMB control
number 0910–0014; the collections of
information in 21 CFR part 314 have
been approved under OMB control
number 0910–0001.
III. Electronic Access
Persons with access to the internet
may obtain the guidance at https://
www.fda.gov/drugs/guidancecompliance-regulatory-information/
guidances-drugs, https://www.fda.gov/
regulatory-information/search-fdaguidance-documents, https://
www.fda.gov/vaccines-blood-biologics/
guidance-compliance-regulatoryinformation-biologics/biologicsguidances, or https://
www.regulations.gov.
Dated: October 27, 2022.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2022–23787 Filed 11–1–22; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Health Resources and Services
Administration
Notice of Request for Public Comment
on Proposed Update to the Bright
Futures Periodicity Schedule as Part of
the HRSA-Supported Preventive
Services Guidelines for Infants,
Children, and Adolescents
Health Resources and Services
Administration (HRSA), Department of
Health and Human Services (HHS).
ACTION: Notice.
AGENCY:
This notice seeks public
comment on a proposed update to the
Periodicity Schedule of the Bright
Futures Recommendations for Pediatric
Preventive Health Care (‘‘Bright Futures
Periodicity Schedule’’), as part of the
HRSA-supported preventive service
guidelines for infants, children, and
adolescents. Please see https://
SUMMARY:
PO 00000
Frm 00071
Fmt 4703
Sfmt 4703
66197
mchb.hrsa.gov/maternal-child-healthtopics/child-health/bright-futures.html
for additional information. Specifically,
the proposed update to the Bright
Futures Periodicity Schedule is to
extend the upper age range for the
existing universal Human
Immunodeficiency Virus (HIV)
screening recommendation.
In the Bright Futures Periodicity
Schedule, a ‘‘dot’’ with an ‘‘arrow’’
indicates a ‘‘range during which a
service may be provided.’’ In the current
Bright Futures Periodicity Schedule, the
age range recommended for which
adolescents may be provided universal
screening for HIV is between the 15-year
visit and 18-year visit. The proposed
update to the Bright Futures Periodicity
Schedule would indicate that the
recommended age range for which
adolescents may be provided universal
screening for HIV is between the 15-year
visit and 21-year visit. The proposed
update also includes an accompanying
footnote to provide updated information
from the American Academy of
Pediatrics (AAP) about more frequent
screening for youth assessed as at high
risk of HIV infection.
DATES: Members of the public are
invited to provide written comments no
later than December 2, 2022. All
comments received on or before this
date will be reviewed and considered by
the Bright Futures Periodicity Schedule
Working Group and provided for further
consideration by HRSA in determining
the recommended updates that it will
support.
ADDRESSES: Members of the public
interested in providing comments can
do so by accessing the public comment
web page at: https://mchb.hrsa.gov/
maternal-child-health-topics/childhealth/bright-futures.html.
FOR FURTHER INFORMATION CONTACT:
Bethany Miller, HRSA, Maternal and
Child Health Bureau, email: BMiller@
hrsa.gov, telephone: (301) 945–5156.
SUPPLEMENTARY INFORMATION: The Bright
Futures Periodicity Schedule is
maintained through a national
cooperative agreement, the Bright
Futures Pediatric Implementation
Program, with the AAP. If accepted by
HRSA, the proposed update to the
Bright Futures Periodicity Schedule will
provide additional clinical guidance to
providers and, under the Public Health
Service Act and pertinent regulations,
would require non-grandfathered group
health plans and health insurance
issuers to provide coverage without
cost-sharing of such updated preventive
care and screenings.
When its preventive care and
screening recommendations have been
E:\FR\FM\02NON1.SGM
02NON1
Federal Register / Vol. 87, No. 211 / Wednesday, November 2, 2022 / Notices
accepted by HRSA, the Bright Futures
Periodicity Schedule is part of the
HRSA-supported preventive service
guidelines for infants, children, and
adolescents. The development of the
Periodicity Schedule is maintained
through a national cooperative
agreement, the Bright Futures Pediatric
Implementation Program, with AAP.
Under Section 2713 of the Public Health
Service Act (42 U.S.C. 300gg–13) and
pertinent regulations, non-grandfathered
group health plans and health insurance
issuers must provide coverage, without
cost sharing, for certain preventive
services for plan years (in the individual
market, policy years) that begin on or
after the date that is 1 year after the date
the recommendation or guideline is
issued. These include HRSA-supported
preventive health services provided for
in the Bright Futures Periodicity
Schedule as part of the HRSA-supported
preventive services guidelines for
infants, children, and adolescents.
Through the cooperative agreement
with the AAP, the Bright Futures
Pediatric Implementation Program is
required to administer a process for
developing and regularly
recommending, as needed, updates to
the Bright Futures Periodicity Schedule
through a process that includes a
comprehensive, objective, and
transparent review of available evidence
that incorporates opportunity for public
comment. Accordingly, the Program
reviews the evidence to determine
whether updates are needed, develops
recommended updates, seeks and
considers public comments, and makes
recommendations to HRSA.
The AAP convenes a panel of
pediatric primary care experts, the
Bright Futures Periodicity Schedule
Working Group, to review the latest
evidence, develop draft recommended
updates, seek and consider public
comment, and propose updates to the
Bright Futures Periodicity Schedule.
Comments received from the public will
be reviewed and discussed by the Bright
Futures Periodicity Schedule Working
Group.
TOPIC
ADOLESCENCE
PROCEDURES
HIV (CUmmt) :io
khammond on DSKJM1Z7X2PROD with NOTICES
HIV (Proposed)'°
11Y 12Y 13Y 14Y 1SY 16Y 17Y 18Y 19Y 20Y 21 Y
•
.
* * * * .
* * * * •
All such screenings (universal and
risk-based) within this age range are
within the scope of the guideline. The
proposed update also includes an
accompanying footnote to provide
updated information from the AAP
about more frequent screening for youth
assessed as at high risk of HIV infection.
The full footnote reads:
Authority: 2713(a)(3) of the Public
Health Service Act, 42 U.S.C. 300gg–
13(a)(3).
‘‘Screen adolescents for HIV at least once
between the ages of 15 and 21 making every
effort to preserve confidentiality of the
adolescent, as per ‘‘Human
Immunodeficiency Virus (HIV) Infection:
Screening’’ (https://www.uspreventive
servicestaskforce.org/uspstf/
recommendation/human-immunodeficiencyvirus-hiv-infection-screening), and after
initial screening, youth at increased risk of
HIV infection should be retested annually or
more frequently, as per ‘‘Adolescents and
Young Adults: The Pediatrician’s Role in HIV
Testing and Pre- and Postexposure HIV
Prophylaxis’’ (https://doi.org/10.1542/
peds.2021-055207).’’
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
VerDate Sep<11>2014
16:38 Nov 01, 2022
Jkt 259001
The proposed update to the Bright
Futures Periodicity Schedule would
indicate that the recommended age
range for which adolescents may be
provided universal screening for HIV is
between the 15-year visit and 21-year
visit. In the current Bright Futures
Periodicity Schedule, the age range
recommended for which adolescents
may be offered universal screening for
HIV is between the 15-year visit and 18year visit. Early detection of an infection
with HIV in adolescents and young
adults can lead to improved health
outcomes and reduce the further spread
of HIV by individuals who are not yet
aware they are infected. Universal
screening is a type of screening that a
provider may recommend without first
identifying a specific risk factor or
symptom.
The current and proposed update to
HIV screening is reflected in the chart
below:
--+
Carole Johnson,
Administrator.
[FR Doc. 2022–23845 Filed 11–1–22; 8:45 am]
December 7, 2022, from 11 a.m.
to 6 p.m. Eastern Time.
Health Resources and Services
Administration
Meeting of the Advisory Committee on
Infant and Maternal Mortality (Formerly
the Advisory Committee on Infant
Mortality)
Health Resources and Services
Administration (HRSA), Department of
Health and Human Services.
ACTION: Notice.
AGENCY:
In accordance with the
Federal Advisory Committee Act, this
notice announces that the Advisory
Committee on Infant and Maternal
Mortality (ACIMM or Committee) has
SUMMARY:
Frm 00072
Fmt 4703
scheduled a public meeting. Information
about ACIMM and the agenda for this
meeting can be found on the ACIMM
website at https://www.hrsa.gov/
advisory-committees/infant-mortality/
index.html.
DATES:
BILLING CODE 4165–15–P
PO 00000
* * *
Sfmt 4703
This meeting will be held
via webinar. The webinar link and login information will be available at the
ACIMM website before the meeting:
https://www.hrsa.gov/advisorycommittees/infant-mortality/.
ADDRESSES:
FOR FURTHER INFORMATION CONTACT:
Vanessa Lee, MPH, Designated Federal
Officer, Maternal and Child Health
Bureau, HRSA, 5600 Fishers Lane,
Room 18N84, Rockville, Maryland
20857; 301–443–0543; or SACIM@
hrsa.gov.
ACIMM is
authorized by section 222 of the Public
Health Service Act (42 U.S.C. 217a), as
amended. The Committee is governed
by provisions of Public Law 92–463, as
amended, (5 U.S.C. App. 2), which sets
SUPPLEMENTARY INFORMATION:
E:\FR\FM\02NON1.SGM
02NON1
EN02NO22.001</GPH>
66198
]]>Agencies
[Federal Register Volume 87, Number 211 (Wednesday, November 2, 2022)]
[Notices]
[Pages 66197-66198]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-23845]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Health Resources and Services Administration
Notice of Request for Public Comment on Proposed Update to the
Bright Futures Periodicity Schedule as Part of the HRSA-Supported
Preventive Services Guidelines for Infants, Children, and Adolescents
AGENCY: Health Resources and Services Administration (HRSA), Department
of Health and Human Services (HHS).
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This notice seeks public comment on a proposed update to the
Periodicity Schedule of the Bright Futures Recommendations for
Pediatric Preventive Health Care (``Bright Futures Periodicity
Schedule''), as part of the HRSA-supported preventive service
guidelines for infants, children, and adolescents. Please see https://mchb.hrsa.gov/maternal-child-health-topics/child-health/bright-futures.html for additional information. Specifically, the proposed
update to the Bright Futures Periodicity Schedule is to extend the
upper age range for the existing universal Human Immunodeficiency Virus
(HIV) screening recommendation.
In the Bright Futures Periodicity Schedule, a ``dot'' with an
``arrow'' indicates a ``range during which a service may be provided.''
In the current Bright Futures Periodicity Schedule, the age range
recommended for which adolescents may be provided universal screening
for HIV is between the 15-year visit and 18-year visit. The proposed
update to the Bright Futures Periodicity Schedule would indicate that
the recommended age range for which adolescents may be provided
universal screening for HIV is between the 15-year visit and 21-year
visit. The proposed update also includes an accompanying footnote to
provide updated information from the American Academy of Pediatrics
(AAP) about more frequent screening for youth assessed as at high risk
of HIV infection.
DATES: Members of the public are invited to provide written comments no
later than December 2, 2022. All comments received on or before this
date will be reviewed and considered by the Bright Futures Periodicity
Schedule Working Group and provided for further consideration by HRSA
in determining the recommended updates that it will support.
ADDRESSES: Members of the public interested in providing comments can
do so by accessing the public comment web page at: https://mchb.hrsa.gov/maternal-child-health-topics/child-health/bright-futures.html.
FOR FURTHER INFORMATION CONTACT: Bethany Miller, HRSA, Maternal and
Child Health Bureau, email: [email protected], telephone: (301) 945-
5156.
SUPPLEMENTARY INFORMATION: The Bright Futures Periodicity Schedule is
maintained through a national cooperative agreement, the Bright Futures
Pediatric Implementation Program, with the AAP. If accepted by HRSA,
the proposed update to the Bright Futures Periodicity Schedule will
provide additional clinical guidance to providers and, under the Public
Health Service Act and pertinent regulations, would require non-
grandfathered group health plans and health insurance issuers to
provide coverage without cost-sharing of such updated preventive care
and screenings.
When its preventive care and screening recommendations have been
[[Page 66198]]
accepted by HRSA, the Bright Futures Periodicity Schedule is part of
the HRSA-supported preventive service guidelines for infants, children,
and adolescents. The development of the Periodicity Schedule is
maintained through a national cooperative agreement, the Bright Futures
Pediatric Implementation Program, with AAP. Under Section 2713 of the
Public Health Service Act (42 U.S.C. 300gg-13) and pertinent
regulations, non-grandfathered group health plans and health insurance
issuers must provide coverage, without cost sharing, for certain
preventive services for plan years (in the individual market, policy
years) that begin on or after the date that is 1 year after the date
the recommendation or guideline is issued. These include HRSA-supported
preventive health services provided for in the Bright Futures
Periodicity Schedule as part of the HRSA-supported preventive services
guidelines for infants, children, and adolescents.
Through the cooperative agreement with the AAP, the Bright Futures
Pediatric Implementation Program is required to administer a process
for developing and regularly recommending, as needed, updates to the
Bright Futures Periodicity Schedule through a process that includes a
comprehensive, objective, and transparent review of available evidence
that incorporates opportunity for public comment. Accordingly, the
Program reviews the evidence to determine whether updates are needed,
develops recommended updates, seeks and considers public comments, and
makes recommendations to HRSA.
The AAP convenes a panel of pediatric primary care experts, the
Bright Futures Periodicity Schedule Working Group, to review the latest
evidence, develop draft recommended updates, seek and consider public
comment, and propose updates to the Bright Futures Periodicity
Schedule. Comments received from the public will be reviewed and
discussed by the Bright Futures Periodicity Schedule Working Group.
The proposed update to the Bright Futures Periodicity Schedule
would indicate that the recommended age range for which adolescents may
be provided universal screening for HIV is between the 15-year visit
and 21-year visit. In the current Bright Futures Periodicity Schedule,
the age range recommended for which adolescents may be offered
universal screening for HIV is between the 15-year visit and 18-year
visit. Early detection of an infection with HIV in adolescents and
young adults can lead to improved health outcomes and reduce the
further spread of HIV by individuals who are not yet aware they are
infected. Universal screening is a type of screening that a provider
may recommend without first identifying a specific risk factor or
symptom.
The current and proposed update to HIV screening is reflected in
the chart below:
[GRAPHIC] [TIFF OMITTED] TN02NO22.001
All such screenings (universal and risk-based) within this age
range are within the scope of the guideline. The proposed update also
includes an accompanying footnote to provide updated information from
the AAP about more frequent screening for youth assessed as at high
risk of HIV infection. The full footnote reads:
``Screen adolescents for HIV at least once between the ages of
15 and 21 making every effort to preserve confidentiality of the
adolescent, as per ``Human Immunodeficiency Virus (HIV) Infection:
Screening'' (https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/human-immunodeficiency-virus-hiv-infection-screening), and after initial screening, youth at increased risk of
HIV infection should be retested annually or more frequently, as per
``Adolescents and Young Adults: The Pediatrician's Role in HIV
Testing and Pre- and Postexposure HIV Prophylaxis'' (https://doi.org/10.1542/peds.2021-055207).''
Authority: 2713(a)(3) of the Public Health Service Act, 42 U.S.C.
300gg-13(a)(3).
Carole Johnson,
Administrator.
[FR Doc. 2022-23845 Filed 11-1-22; 8:45 am]
BILLING CODE 4165-15-P
